Showing 981-987 of 987 results for "".
Weighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://practicaldermatology.com/series/the-practical-dermatology-podcast/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clPruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
https://practicaldermatology.com/programs/cme/pruritus-cases-from-the-field-real-world-perspectives-on-managing-ckd-ap/14969/Did you know that many patients on dialysis suffer from itch, or pruritus? Hear patients describe their experiences with a new FDA-approved therapy.Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
https://practicaldermatology.com/programs/cme/targeting-il-13-in-moderate-to-severe-atopic-dermatitis-forging-a-new-path-to-improved-disease-and-patient-outcomes/16384/Get expert insights on incorporating novel agents to optimize care for patients with atopic dermatitis, including those targeting interleukin (IL)-13.How do you manage a complex medical referral?
https://practicaldermatology.com/topics/practice-management/how-do-you-manage-a-complex-medical-referral-/18794/Management of complex medical dermatology referrals has evolved, says Joseph Jorizzo, MD, FAAD, Professor; Former & Founding Chair, Dermatology Dept., Wake Forest University and Professor of Dermatology, Weill Cornell Medical College. In this edition of Ask an Expert, he talks to host Adam FriedPipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investigDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveTaking the Patient-Centered Approach to Mycophenolate Risk Mitigation
https://practicaldermatology.com/programs/cme/taking-the-patient-centered-approach-to-mycophenolate-risk-mitigation-mycophenolate-risk-mitigation/16628/Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation.
- Previous
- Next